RAD December 2023 Abstracts and Posters
All accepted abstracts have been publised in The British Journal of Dermatology. You may access the publication at: https://academic.oup.com/bjd/issue/188/1482 - Efficacy and safety of sequential topical 0.1% mometasone furoate cream and 2% crisaborole in the treatment of mild to moderate atopic dermatitis in children aged over 2 years—a multicentre parallel randomised controlled study in China
Huan Yang, Hong Shu, Limin Miao, Ping Li, Shan Wang, Hua Qian, Zhenping Chen, Xiaoyan Luo, Lin Ma and Hua Wang
484 - Phase 2 Trial in Progress— Lirentelimab in Adults with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments
Cristian Rodriguez MD, Anesa Moyer, Alan T. Chang, Enoch Bortey PhD, and Craig Paterson MD
487 - Adult Atopic dermatitis is associated with impaired oral health and oral dysbiosis - a case-control study
Aaya Shahin, Yael A. Leshem, Yossi Taieb MD, Sharon Baum, Aviv Barzilai, Danielle Jedda, Efrat Sharon, Omry Koren, Shunit Coppenhagen-Glazer, Ronen Hazan, Yael Houri-Haddad, Shoshana Greenberger
493 - Lebrikizumab does not impact vaccine-induced immune responses: results from a phase 3 study in adult patients with moderate-to-severe atopic dermatitis
Jennifer Soung, Vivian Laquer, Joseph F. Merola, Seth Forman, Hany Elmaraghy, Eric Meskimen, Chaoran Hu, Chitra R. Natalie, Evangeline Pierce, Hitoe Torisu-Itakura, Esther Garcia Gil, Abel D. Jarell
494 - Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
Alan Irvine, Lynda Spelman, Jonathan Silverberg, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline Pierce, Laia Bardolet, Diamant Thaci
495 - Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
Emma Guttman-Yassky, Angela Okragly, Zhe Sun, Laura Rebeca Mena, Nathan Hahn, Brian J. Nickoloff, Kimberly Siu, Gaia Gallo, Eric Wolf, Kilian Eyerich, Monica Aparici, and Robert J. Benschop
496 - Conjunctivitis does not increase with longer duration of lebrikizumab exposure in patients with moderate-to-severe atopic dermatitis
April Armstrong, Andreas Wollenberg, Marjolein de Bruin-Weller, Peter Lio, Chitra R. Natalie, Fangyi Zhao, Amber Reck Atwater, Gemma Jimenez, Chia-Yu Chu, Christian Vestergaard
497 - Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis
Gil Yosipovitch, Peter A. Lio, David Rosmarin, Marta Casillas, Fan Emily Yang, Chaoran Hu, Evangeline Pierce, Franz J. Legat, Jose-Manuel Carrascosa, Heidi Crane, Laia Boncompte, Sonja Stander
498 - Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study
Hermenio Lima, José-Juan Pereyra-Rodriguez, Jennifer Beecker, Charles W. Lynde, Cristina Sancho, Michael Lane, Hongwei Wang, Brian M. Calimlim, Yolanda Armendariz, Melinda J. Gooderham
502 - Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results
Jonathan I. Silverberg; Emma Guttman-Yassky; Eric L. Simpson; Kim A. Papp; Andrew Blauvelt; Chia-Yu Chu; H. Chih-ho Hong; Linda F. Stein Gold; Thomas Bieber; Kenji Kabashima; David Rosmarin; Amy Gamelli; Brian Calimlim; Namita Vigna; Xiaofei Hu; Yang Yang; Xiaoqiang Wu; Xiaohong Huang; Smitha Suravaram; Henrique D. Teixeira; Eliza Raymundo; Alan D Irvine